Suppr超能文献

日本研发的血液净化膜及其他材料的血液相容性。

The blood compatibilities of blood purification membranes and other materials developed in Japan.

作者信息

Abe Takaya, Kato Karen, Fujioka Tomoaki, Akizawa Tadao

机构信息

Department of Blood Purification Therapy & Urology, Iwate Medical University, School of Medicine, Iwate 020-8505, Japan.

出版信息

Int J Biomater. 2011;2011:375390. doi: 10.1155/2011/375390. Epub 2011 Sep 28.

Abstract

The biocompatibilities in blood purification therapy are defined as "a concept to stipulate safety of blood purification therapy by an index based on interaction in the body arising from blood purification therapy itself." The biocompatibilities are associated with not only materials to be used but also many factors such as sterilization method and eluted substance. It is often evaluated based on impacts on cellular pathways and on humoral pathways. Since the biocompatibilities of blood purification therapy in particular hemodialysis are not just a prognostic factor for dialysis patients but a contributory factor for long-term complications, it should be considered with adequate attention. It is important that blood purification therapy should be performed by consistently evaluating not only risks associated with these biocompatibilities but also the other advantages obtained from treatments. In this paper, the biocompatibilities of membrane and adsorption material based on Japanese original which are used for blood purification therapy are described.

摘要

血液净化治疗中的生物相容性被定义为“一种通过基于血液净化治疗本身在体内产生的相互作用的指标来规定血液净化治疗安全性的概念”。生物相容性不仅与所使用的材料有关,还与许多因素有关,如灭菌方法和洗脱物质。它通常根据对细胞途径和体液途径的影响来评估。由于血液净化治疗尤其是血液透析的生物相容性不仅是透析患者的预后因素,也是长期并发症的促成因素,因此应给予充分关注。重要的是,血液净化治疗应通过持续评估与这些生物相容性相关的风险以及从治疗中获得的其他益处来进行。本文描述了基于日本原著的用于血液净化治疗的膜和吸附材料的生物相容性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cf1/3182377/48d74930ee60/IJBM2011-375390.001.jpg

相似文献

1
The blood compatibilities of blood purification membranes and other materials developed in Japan.
Int J Biomater. 2011;2011:375390. doi: 10.1155/2011/375390. Epub 2011 Sep 28.
3
2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.
4
A novel approach for blood purification: mixed-matrix membranes combining diffusion and adsorption in one step.
Acta Biomater. 2012 Jul;8(6):2279-87. doi: 10.1016/j.actbio.2012.03.008. Epub 2012 Mar 9.
7
Dialysis membranes for blood purification.
Front Med Biol Eng. 2000;10(2):117-29. doi: 10.1163/15685570052061973.
8
Preparation of ultrapure dialysate in Japan--clinical usefulness and short-term future.
Blood Purif. 2004;22 Suppl 2:55-9. doi: 10.1159/000081876.
10
Comparison of biocompatibility in polysulfone dialysis membranes with different sterilization.
Hemodial Int. 2018 Oct;22(S2):S10-S14. doi: 10.1111/hdi.12698. Epub 2018 Nov 8.

引用本文的文献

2
Polymeric Membranes for Biomedical Applications.
Polymers (Basel). 2023 Jan 25;15(3):619. doi: 10.3390/polym15030619.

本文引用的文献

1
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
Ther Apher Dial. 2009 Dec;13(6):505-8. doi: 10.1111/j.1744-9987.2009.00780.x.
4
Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.
Curr Pharm Des. 2009;15(18):2110-9. doi: 10.2174/138161209788489104.
6
Effects of fluid flow on elution of hydrophilic modifier from dialysis membrane surfaces.
J Artif Organs. 2008;11(3):148-55. doi: 10.1007/s10047-008-0417-4. Epub 2008 Oct 5.
8
Oxidative stress in hemodialysis.
Contrib Nephrol. 2008;161:132-137. doi: 10.1159/000130658.
9
A multicenter study of leukocytapheresis in rheumatoid arthritis.
Clin Exp Rheumatol. 2007 Nov-Dec;25(6):810-6.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验